Earnings summaries and quarterly performance for Medpace Holdings.
Executive leadership at Medpace Holdings.
Board of directors at Medpace Holdings.
Research analysts who have asked questions during Medpace Holdings earnings calls.
AH
Ann Hynes
Mizuho Financial Group
6 questions for MEDP
Also covers: ACHC, ARDT, BTSG +21 more
CR
Charles Rhyee
TD Cowen
6 questions for MEDP
Also covers: AMWL, BTSG, CAH +20 more
Jailendra Singh
Truist Securities
6 questions for MEDP
Also covers: ACCD, AGL, AMWL +16 more
JB
Justin Bowers
Deutsche Bank AG
6 questions for MEDP
Also covers: AMED, CON, CRL +9 more
DW
David Windley
Jefferies Financial Group Inc.
5 questions for MEDP
Also covers: CERT, CNC, CRL +15 more
EC
Eric Coldwell
Robert W. Baird & Co.
4 questions for MEDP
Also covers: ACH, AHCO, CAH +11 more
MS
Max Smock
William Blair & Company
4 questions for MEDP
Also covers: CDMO, CERT, CRL +8 more
DL
Daniel Leonard
Stifel Financial Corp.
3 questions for MEDP
Also covers: A, AVTR, BIO +15 more
Luke Sergott
Barclays
3 questions for MEDP
Also covers: A, AVTR, BRKR +20 more
Christine Rains
William Blair
2 questions for MEDP
Also covers: CERT, CRL, ICLR +3 more
Daniel Clark
Leerink Partners
2 questions for MEDP
Also covers: CERT, ELAN, IDXX +6 more
DL
Dan Leonard
UBS Group AG
2 questions for MEDP
Also covers: A, AVTR, BIO +13 more
Jay Lewis
Robert W. Baird & Co. Incorporated
2 questions for MEDP
Also covers: OMI, PINC
Michael Cherny
Leerink Partners
2 questions for MEDP
Also covers: ACCD, ACH, AKBA +23 more
Sean Dodge
RBC Capital Markets
2 questions for MEDP
Also covers: BTSG, CDMO, CTLT +14 more
Dave Windley
Jefferies LLC
1 question for MEDP
Also covers: CERT, CNC, CRL +8 more
KC
Kyle Crews
UBS
1 question for MEDP
Also covers: CERT, CYRX, MRVI
Recent press releases and 8-K filings for MEDP.
Medpace Holdings Under Investigation Following Q4 2025 Book-to-Bill Miss
MEDP
Legal Proceedings
Demand Weakening
Guidance Update
- Levi & Korsinsky, LLP is investigating Medpace Holdings, Inc. for potential securities law claims regarding alleged inconsistencies in statements about its clinical-trial booking pipeline, specifically concerning elevated cancellation rates and a deteriorating book-to-bill ratio.
- On February 9, 2026, Medpace reported a Q4 2025 book-to-bill ratio of 1.04, a significant drop from its historical range of 1.10-1.25, with CEO August Troendle noting cancellations were "the highest in over a year".
- This disclosure contradicted prior optimistic statements from Q1-Q3 2025 earnings calls regarding expected book-to-bill ratios and cancellation rates.
- Medpace shares fell approximately 15.9% on February 10, 2026, driven by the bookings miss, despite Q4 2025 revenue of $708.5 million and GAAP EPS of $4.67 exceeding consensus estimates.
- The company's ending backlog as of December 31, 2025, was approximately $3 billion, reflecting only 4.3% year-over-year growth.
Feb 18, 2026, 2:00 PM
Medpace Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance
MEDP
Earnings
Guidance Update
Share Buyback
- Medpace reported Q4 2025 revenue of $708.5 million, a 32% year-over-year increase, and full year 2025 revenue of $2.53 billion, up 20% from 2024. Full year diluted earnings per share (EPS) was $15.28.
- The company provided full year 2026 guidance, projecting revenue between $2.755 billion and $2.855 billion and diluted EPS between $16.68 and $17.50.
- Backlog cancellations were elevated in Q4 2025, the highest in over a year, resulting in a net book-to-bill ratio of 1.04. These cancellations were widespread but skewed towards the Metabolic area.
- In 2025, Medpace repurchased 2.96 million shares for $912.9 million and expects 2026 headcount growth to be in the mid to high single-digit area.
Feb 10, 2026, 2:00 PM
Medpace Holdings Announces Strong Q4 and Full Year 2025 Results and Provides 2026 Guidance
MEDP
Earnings
Guidance Update
Share Buyback
- Medpace Holdings reported strong financial results for Q4 2025, with revenue increasing by 32.0% to $708.5 million and diluted EPS growing by 27.2% to $4.67 compared to Q4 2024.
- For the full year 2025, revenue reached $2,530.2 million, a 20.0% increase year-over-year, and diluted EPS was $15.28, up 21.0% from 2024.
- Net New Business Awards for Q4 2025 were $736.6 million, resulting in a Net Book-to-Bill ratio of 1.04x, and the ending backlog stood at $3,027.2 million.
- The company generated $188.1 million in Free Cash Flow during Q4 2025, contributing to a full-year Free Cash Flow of $681.9 million, and held $669.4 million in cash and cash equivalents.
- Medpace Holdings provided full-year 2026 guidance, projecting revenue between $2,755.0 million and $2,855.0 million, and diluted EPS between $16.68 and $17.50.
Feb 10, 2026, 2:00 PM
Medpace Holdings Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance
MEDP
Earnings
Guidance Update
Share Buyback
- Medpace Holdings reported Q4 2025 revenue of $708.5 million, a 32% year-over-year increase, and full year 2025 revenue of $2.53 billion, up 20% from 2024. Net income per diluted share was $4.67 for Q4 2025 and $15.28 for full year 2025.
- Net new business awards for Q4 2025 were $736.6 million, resulting in a net book-to-bill ratio of 1.04, which was lower than anticipated due to elevated cancellations. The ending backlog as of December 31, 2025, was approximately $3 billion.
- For full year 2026, Medpace projects total revenue in the range of $2.755 billion to $2.855 billion and earnings per diluted share between $16.68 and $17.50.
- The company repurchased 2.96 million shares for $912.9 million in full year 2025 and anticipates headcount growth in 2026 to be in the mid to high single-digit area, exceeding 2025 levels, driven by improved retention and productivity.
Feb 10, 2026, 2:00 PM
Medpace Holdings Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance
MEDP
Earnings
Guidance Update
Share Buyback
- Medpace reported Q4 2025 revenue of $708.5 million, a 32% year-over-year increase, and full year 2025 revenue of $2.53 billion, up 20% from 2024. Full year 2025 diluted EPS was $15.28.
- Net new business awards in Q4 2025 were $736.6 million, resulting in a net book-to-bill ratio of 1.04. However, backlog cancellations were elevated in Q4, the highest in over a year, and were widespread but skewed towards the metabolic area.
- For the full year 2025, Medpace repurchased 2.96 million shares for $912.9 million.
- The company issued full year 2026 guidance, projecting revenue between $2.755 billion and $2.855 billion and diluted earnings per share in the range of $16.68 to $17.50.
- Medpace anticipates mid to high single-digit headcount growth in 2026, driven by continued good retention and improved productivity.
Feb 10, 2026, 2:00 PM
Medpace Reports Strong Q4 and Full-Year 2025 Results
MEDP
Earnings
Revenue Acceleration/Inflection
Guidance Update
- Medpace reported strong Q4 2025 results, with GAAP EPS of $4.67 and revenue of $708.45 million, representing a 32% year-over-year increase.
- For full-year 2025, the company delivered approximately 20% revenue growth to about $2.53 billion, with net income of $451.1 million and diluted EPS of $15.28.
- The Q4 earnings surprise was about +11.79% to the Zacks Consensus, and Medpace has topped consensus EPS estimates in each of the last four quarters.
- Despite these robust results, the stock has modestly underperformed year-to-date, with near-term performance dependent on management's forward commentary.
Feb 9, 2026, 9:23 PM
Medpace Holdings, Inc. Reports Strong Q4 and Full Year 2025 Results, Provides 2026 Guidance
MEDP
Earnings
Guidance Update
Share Buyback
- Medpace Holdings, Inc. reported revenue of $708.5 million for Q4 2025, an increase of 32.0% from the prior-year period, and full-year 2025 revenue of $2,530.2 million, up 20.0% from 2024.
- GAAP net income for Q4 2025 was $135.1 million ($4.67 per diluted share), and for the full year 2025, it was $451.1 million ($15.28 per diluted share).
- The company's backlog as of December 31, 2025, increased 4.3% to $3,027.2 million, with net new business awards of $736.6 million in Q4 2025, resulting in a net book-to-bill ratio of 1.04x.
- In full year 2025, Medpace repurchased 2,961,924 shares for a total of $912.9 million, with $821.7 million remaining under its authorized share repurchase program as of December 31, 2025.
- For 2026, Medpace forecasts revenue in the range of $2.755 billion to $2.855 billion and diluted earnings per share between $16.68 and $17.50.
Feb 9, 2026, 9:15 PM
Medpace Holdings Reports Strong Q4 and Full Year 2025 Results, Issues 2026 Guidance
MEDP
Earnings
Guidance Update
Share Buyback
- Medpace Holdings reported strong financial results for Q4 2025, with revenue increasing by 32.0% to $708.5 million and GAAP net income reaching $135.1 million, or $4.67 per diluted share.
- For the full year 2025, revenue grew 20.0% to $2,530.2 million, and GAAP net income was $451.1 million, or $15.28 per diluted share.
- Net new business awards were $736.6 million in Q4 2025, leading to a net book-to-bill ratio of 1.04x, and 1.05x for the full year 2025, indicating continued growth in backlog.
- The company provided 2026 financial guidance, forecasting revenue between $2.755 billion and $2.855 billion and diluted earnings per share (GAAP) in the range of $16.68 to $17.50.
- In 2025, Medpace repurchased 2,961,924 shares for $912.9 million, with $821.7 million remaining under its share repurchase program as of December 31, 2025.
Feb 9, 2026, 9:15 PM
Medpace Holdings, Inc. Announces Third Quarter 2025 Results and Full Year Guidance
MEDP
Earnings
Guidance Update
Share Buyback
- Medpace Holdings, Inc. reported Q3 2025 revenue of $659.9 million, a 23.7% increase from the prior-year period, with GAAP net income of $111.1 million and $3.86 per diluted share.
- Net new business awards for Q3 2025 increased 47.9% year-over-year to $789.6 million, resulting in a net book-to-bill ratio of 1.20x.
- The company's backlog as of September 30, 2025, grew 2.5% to $3,000.6 million.
- Medpace forecasts full year 2025 revenue between $2.480 billion and $2.530 billion and diluted earnings per share in the range of $14.60 to $14.86.
- For the nine months ended September 30, 2025, the company repurchased 2,961,924 shares for a total of $912.9 million.
Oct 22, 2025, 8:15 PM
Quarterly earnings call transcripts for Medpace Holdings.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more